Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

ARCT-032 for Cystic Fibrosis (CF): The LunairCF ... Arcturus' self-amplifying mRNA (SAM-RNA) technology represents a potential game-changer in the field of mRNA therapeutics and vaccines.

ARCT-810 for OTCD (Phase 2 data 1H '25) must prove IV dosing every 2 weeks is worth better outcomes vs. current treatments; ammonia reduction key measure of success. ARCT-032 for CF (Phase 2 data ...

ARCT opened at $17.12 on Friday. The stock has a market cap of $463.78 million, a PE ratio of -7.71 and a beta of 2.63. The business has a 50 day moving average of $17.28 and a 200-day moving ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Ed Arce has given his Buy ...

SAN DIEGO, January 10, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for Arcturus Therapeutics in a report released on Tuesday ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Discover outperforming stocks ...

Microsoft’s Game Pass subscription service enters 2025 bigger than ever, after finishing 2024 by adding two massive day-one blockbuster games: Call of Duty: Black Ops 6 and Indiana Jones and the ...